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Clostridium difficile (reclassified as Clostridioides difficile [1]), first described 85 years ago
as a commensal microorganism in the feces of a newborn infant, has drawn further attention
due to its involvement in intestinal infection that lead to high morbidity and mortality
among individuals of different ages in healthcare and the community. It has also emerged
as a zoonotic pathogen since highly genetically similar C. difficile isolates were characterized
in humans, pets and farm animals [2,3]. Indeed, livestock can serve as a potential reservoir
for C. difficile and pose a threat to humans since the spores facilitate the rapid spread of
this bacterium in the environment. Although antimicrobial resistance is common among
C. difficile [4], widespread antibiotic use in healthcare and animal husbandry has led to
the development of multiresistant types, making the treatment of C. difficile infections
(CDI) even more difficult [5]. Moreover, due to its anaerobic metabolism and relatively
slow growth compared with other bacterial pathogens, research on C. difficile faces many
challenges. However, in recent decades, significant advances in molecular methods has
made possible a better understanding of the physiology and epidemiology of C. difficile in
animals and humans [4,6,7].
C. difficile is one of the pioneer microbial colonizers in animals and humans. In farm
animals such as pigs, an immature yet developing microbiota allows for the outgrowth of
C. difficile, including toxigenic types, which may lead to infection [8,9]. It is noteworthy
that concentrations of C. difficile and its toxins in neonatal piglets peak quickly during the
first week and diminish from the second week onwards [9]. Therefore, a very short time
window for C. difficile colonization, including toxin-producing types, can be observed. Such
an observation is also true for infants. However, the lack of toxin-receptor expression or
toxin-neutralizing antibodies at such early age has been suggested as a reason that infants
are protected against CDI development [10]. On the other hand, in adult humans C. difficile
outgrowth and infections have been associated with microbial dysbiosis in the gut caused
by comorbidities, the use of antimicrobials or advanced age [11,12]. Recently, it has been
suggested that a decreased expression of the High Mobility Group Box 1 HMGB1 cytokine
in peripheral blood is involved in the diminished capability of elderly patients with CDI to
fight the pathogen [7]. Indeed, reports show that microbial diversity is decreased in both
C. difficile-colonized and CDI patients, and certain bacteria have been identified as playing
a key role in colonization resistance against C. difficile and CDI development [13,14].
Lately, an in vitro study has demonstrated that sow colostrum, which contains anti-
bodies against C. difficile toxins, may protect intestinal porcine cell lines from toxin-induced
effects [15,16]. Moreover, the administration of antibodies against C. difficile toxins can
protect all experimentally challenged piglets from developing systemic infection and mini-
mize intestinal lesions [17]. Therefore, sufficient antibody titers against toxins transferred
from mother to offspring through colostrum may be crucial in passive protection against
gut intoxication and infection development once C. difficile colonization has been estab-
lished in the piglet gut. In humans, clinical studies have identified protective antibodies
against C. difficile toxins in the blood of patients who have suffered from CDI [18]. Further,
a successful development of an antibody vaccine that neutralizes C. difficile toxin B has
been demonstrated [19]. Finally, a recent study has identified a new immunoreactive
surface protein isolated from C. difficile that is recognized by human blood and umbilical
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cord blood sera; therefore, it could serve a future use in preventive vaccine construction
for humans [20].
The abovementioned studies demonstrate significant progress in the research on
C. difficile. However, there are still many open questions regarding it, such as how healthy
animal and human carriers of C. difficile and its toxins can remain free of symptoms or
why there is a very short time window for colonization of C. difficile in certain farm animal
species. Successful strategies to prevent and treat CDI in animals and humans while
reducing the antimicrobial use are also needed.
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Long-term antibiotic prophylaxis in urology and high incidence of clostridioides difficile infections in surgical adult patients.
Microorganisms 2020, 8, 810. [CrossRef] [PubMed]
12. Kachrimanidou, M.; Tsintarakis, E. Insights into the role of human gut microbiota in clostridioides difficile infection. Microorgan-
isms 2020, 8, 200. [CrossRef] [PubMed]
13. Crobach, M.J.T.; Ducarmon, Q.R.; Terveer, E.M.; Harmanus, C.; Sanders, I.M.J.G.; Verduin, K.M.; Kuijper, E.J.; Zwittink, R.D. The
bacterial gut microbiota of adult patients infected, colonized or noncolonized by clostridioides difficile. Microorganisms 2020, 8, 677.
[CrossRef] [PubMed]
14. Buffie, C.G.; Bucci, V.; Stein, R.R.; McKenney, P.T.; Ling, L.; Gobourne, A.; No, D.; Liu, H.; Kinnebrew, M.; Viale, A.; et al. Precision
microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015, 517, 205–208. [CrossRef]
[PubMed]
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